Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | PBI-200 |
| Synonyms | |
| Therapy Description |
PBI-200 is a pan-NTRK inhibitor with activity against resistance mutations, which potentially reduces tumor cell proliferation and tumor growth (Cancer Res 2019;79(13 Suppl):Abstract nr 2198). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| PBI-200 | PBI 200|PBI200 | Trk Receptor Inhibitor (Pan) 33 | PBI-200 is a pan-NTRK inhibitor with activity against resistance mutations, which potentially reduces tumor cell proliferation and tumor growth (Cancer Res 2019;79(13 Suppl):Abstract nr 2198). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04901806 | Phase Ib/II | PBI-200 | Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors | Terminated | USA | ITA | GBR | FRA | ESP | DNK | DEU | AUS | 3 |